Legend Biotech Co. (NASDAQ:LEGN – Get Free Report) was the target of a large decrease in short interest in June. As of June 15th, there was short interest totalling 11,000,000 shares, a decrease of 17.0% from the May 31st total of 13,260,000 shares. Based on an average daily volume of 1,130,000 shares, the days-to-cover ratio is presently 9.7 days.
Legend Biotech Stock Performance
Shares of NASDAQ LEGN traded down $0.37 during midday trading on Friday, reaching $44.29. 571,398 shares of the stock were exchanged, compared to its average volume of 1,326,152. The company has a quick ratio of 5.57, a current ratio of 5.66 and a debt-to-equity ratio of 0.25. The firm has a market cap of $8.07 billion, a price-to-earnings ratio of -34.07 and a beta of 0.09. The firm has a 50-day simple moving average of $43.79 and a two-hundred day simple moving average of $53.70. Legend Biotech has a twelve month low of $38.60 and a twelve month high of $77.32.
Legend Biotech (NASDAQ:LEGN – Get Free Report) last announced its quarterly earnings results on Monday, May 13th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.13. Legend Biotech had a negative net margin of 135.92% and a negative return on equity of 27.91%. The firm had revenue of $93.90 million for the quarter, compared to the consensus estimate of $143.24 million. During the same period in the prior year, the firm posted ($0.40) earnings per share. The firm’s quarterly revenue was up 158.7% compared to the same quarter last year. As a group, analysts anticipate that Legend Biotech will post -1.93 EPS for the current fiscal year.
Institutional Investors Weigh In On Legend Biotech
Wall Street Analysts Forecast Growth
LEGN has been the subject of several research reports. Truist Financial initiated coverage on shares of Legend Biotech in a research note on Monday, June 17th. They set a “buy” rating and a $88.00 price objective for the company. Cantor Fitzgerald assumed coverage on Legend Biotech in a research note on Wednesday, April 3rd. They set an “overweight” rating and a $82.00 price target on the stock. Raymond James began coverage on Legend Biotech in a research note on Wednesday, March 13th. They issued an “outperform” rating and a $86.00 price objective for the company. Deutsche Bank Aktiengesellschaft started coverage on Legend Biotech in a research report on Thursday, May 23rd. They issued a “buy” rating and a $60.00 target price on the stock. Finally, Scotiabank raised shares of Legend Biotech from a “sector perform” rating to a “sector outperform” rating and set a $65.00 price target for the company in a research report on Wednesday, April 17th. Thirteen analysts have rated the stock with a buy rating, According to MarketBeat, Legend Biotech presently has a consensus rating of “Buy” and a consensus target price of $81.67.
View Our Latest Stock Analysis on Legend Biotech
Legend Biotech Company Profile
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM).
Featured Articles
- Five stocks we like better than Legend Biotech
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- Upwork Stock’s Outlook: Numbers Solid Despite Gen-AI Challenges
- 3 Warren Buffett Stocks to Buy Now
- What’s Behind Walgreens Stock Plunge: What Investors Can Do Next
- Investing in Travel Stocks Benefits
- MarketBeat Week in Review – 6/24 – 6/28
Receive News & Ratings for Legend Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Legend Biotech and related companies with MarketBeat.com's FREE daily email newsletter.